Eric J. Loumeau Sells 3,895 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric J. Loumeau sold 3,895 shares of AnaptysBio stock in a transaction on Monday, September 18th. The shares were sold at an average price of $19.32, for a total transaction of $75,251.40. Following the completion of the sale, the insider now owns 882 shares in the company, valued at $17,040.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

AnaptysBio Trading Down 1.2 %

Shares of ANAB stock traded down $0.23 during trading hours on Monday, reaching $19.27. 219,916 shares of the stock were exchanged, compared to its average volume of 263,160. AnaptysBio, Inc. has a 12-month low of $16.66 and a 12-month high of $32.44. The company’s 50-day moving average price is $19.23 and its 200-day moving average price is $20.18. The firm has a market capitalization of $511.62 million, a price-to-earnings ratio of -3.71 and a beta of -0.16.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.50) EPS for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.15. AnaptysBio had a negative net margin of 1,113.38% and a negative return on equity of 65.52%. The firm had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $5.50 million. On average, sell-side analysts expect that AnaptysBio, Inc. will post -6.52 EPS for the current year.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of research reports. Wedbush reduced their price target on shares of AnaptysBio from $29.00 to $26.00 and set a “neutral” rating on the stock in a report on Tuesday, August 8th. JPMorgan Chase & Co. upgraded shares of AnaptysBio from an “underweight” rating to a “neutral” rating and reduced their target price for the stock from $31.00 to $30.00 in a report on Monday, May 22nd. Finally, StockNews.com downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.80.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in AnaptysBio in the 2nd quarter valued at about $34,000. BNP Paribas Arbitrage SA boosted its position in AnaptysBio by 75.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 2,142 shares during the period. Fred Alger Management LLC purchased a new stake in AnaptysBio in the 4th quarter valued at about $191,000. Delphia USA Inc. purchased a new stake in AnaptysBio in the 1st quarter valued at about $233,000. Finally, Jane Street Group LLC boosted its position in AnaptysBio by 14.8% in the 4th quarter. Jane Street Group LLC now owns 9,647 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 1,244 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.